白蛋白结合型紫杉醇(Albumin-Bound Paclitaxel) - 药物靶点：Tubulin_在研适应症：胰腺继发性恶性肿瘤，转移性胰腺腺癌，胰腺腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Nab-Paclitaxel、Nab-PTX、Paclitaxel (albumin-bound)

+ [13]

靶点

Tubulin

作用机制

微管蛋白抑制剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [6]

在研适应症

胰腺继发性恶性肿瘤转移性胰腺腺癌胰腺腺癌+ [36]

非在研适应症

大肠腺癌前列腺腺癌小肠腺癌+ [77]

原研机构

Abraxis BioScience, Inc.

在研机构

Hoffmann-La Roche, Inc.

石药集团有限公司

Celgene Corp.

+ [13]

非在研机构

Genentech, Inc.

GSK Plc

石药集团中奇制药技术（天津）有限公司

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (2005-01-07),

转移性乳腺癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

关联

1,411

项与白蛋白结合型紫杉醇相关的临床试验

NCT06675136 / Not yet recruiting临床1期IIT

Phase 1 Trial of Nab-Paclitaxel PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) Given in Combination With Second-Line Therapy for Gastric Cancer With Peritoneal Metastases

This phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that has spread from where it first started to the tissue that lines the abdominal wall and organs (peritoneal metastases). Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. PIPAC delivers chemotherapy, such as nab-paclitaxel, that has been turned into a fine mist (aerosolized) at a high pressure directly into the abdominal cavity. Aerosolized chemotherapy delivered directly into the peritoneal space has been shown to deliver higher drug concentrations to the tumor. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab may be safe, tolerable, and/or effective in treating gastric cancer patients with peritoneal metastases.

开始日期2025-10-17

申办/合作机构

City of Hope National Medical Center

[+1]

NCT06704724 / Not yet recruiting临床1期

A Phase 1 Open-Label Study of PF-07985045 as A Single-Agent and in Combination With Other Anti-Cancer Agents in Participants With Advanced Solid Tumors

The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
This study also aims to find the best amount of study medication.
This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that:
* are advanced (cancer that doesn't disappear or stay away with treatment) and
* have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers).
This includes (but limited to) the following cancer types:
* Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body.
* Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control.
* Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels.
All participants in this study will take the study medication (PF-07985045) as pill by mouth once a day. This will be repeated for 21-day or 28-day cycles.
Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07985045 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at different times (depending on the treatment) during the 21-day or 28-day cycle.
Participants can continue to take the study medication (PF-07985045) and the combination anti-cancer therapy until their cancer is no longer responding.
The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective.
Participants will be in this study for up to 4 years. During this time, the participants will come into the clinic for 1 to 4 times in each 21-day or 28-day cycle. After the participants have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing

开始日期2025-01-13

申办/合作机构

Pfizer Inc.

NCT06692491 / Not yet recruiting临床2期IIT

A Phase II Clinical Study on Precision Treatment of Rare Tumours in China Guided by Patient-Derived Tumor Organoids (PDO) and Next-Generation Sequencing (NGS)

The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug screening.

开始日期2025-01-01

申办/合作机构

北京大学深圳医院

100 项与白蛋白结合型紫杉醇相关的临床结果

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的转化医学

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的专利（医药）

登录后查看更多信息

3,038

项与白蛋白结合型紫杉醇相关的文献（医药）

2025-02-01·Biomaterials advances

Tailoring metabolic activity assays for tumour-engineered 3D models

Article

作者: Croagh, Daniel ; Gabrielyan, Anastasiia ; Loessner, Daniela ; Hauser, Sandra ; Curvello, Rodrigo ; Clegg, Julien

Monitoring cell behaviour in hydrogel-based 3D models is critical for assessing their growth and response to cytotoxic treatment. Resazurin-based PrestoBlue and AlamarBlue reagents are frequently used metabolic activity assays when determining cell responses. However, both assays are largely applied to cell monolayer cultures but yet to have a defined protocol for use in hydrogel-based 3D models. The assays' performance depends on the cell type, culture condition and measurement sensitivity. To better understand how both assays perform, we grew pancreatic cancer cells in gelatin methacryloyl and collagen hydrogels and evaluated their metabolic activity using different concentrations and incubation times of the PrestoBlue and AlamarBlue reagents. We tested reagent concentrations of 4 % and 10 % and incubation times of 45 min, 2 h and 4 h. In addition, we co-cultured cancer cells together with cancer-associated fibroblasts and peripheral blood mononuclear cells in gelatin methacryloyl hydrogels and subjected them to gemcitabine and nab-paclitaxel to evaluate how both assays perform when characterising cell responses upon drug treatment. CyQuant assays were conducted on the same samples and compared to data from the metabolic activity assays. In cancer monocultures, higher reagent concentration and incubation time increased fluorescent intensity. We found a reagent concentration of 10 % and an incubation time of 2 h suitable for all cell lines and both hydrogels. In multicellular 3D cultures, PrestoBlue and AlamarBlue assays detected similar cell responses upon drug treatment but overestimated cell growth. We recommend to assess cell viability and growth in conjunction with CyQuant assays that directly measure cell functions.

2025-01-01·Current cancer drug targets

Twenty-four-month Progression-free Survival in HER2-amplified Advanced Gastric Cancer with Brain Metastases after Trastuzumab Deruxtecan Treatment: A Case Report and Literature Review

作者: Xu, Min ; Zhang, Haibo

Background::

Trastuzumab deruxtecan (T-DXd) has shown promising outcomes as a second or subsequent-line treatment for human epidermal growth factor-2 (HER2)-positive advanced gastric or gastroesophageal junction cancer.

Case Presentation::

We reported a 49-year-old male patient with stage IV HER2-amplified gastric cancer. Despite extensive pretreatments, including first-line trastuzumab plus FOLFOX, second-- line trastuzumab plus FOLFOX, followed by traditional Chinese medicine, third-line nivolumab plus trastuzumab, fourth-line pyrotinib plus paclitaxel and five hepatic arterial chemoembolization procedures, and fifth-line pembrolizumab plus nab-paclitaxel and thoracic radiotherapy, the patient experienced disease progression. In April 2021, T-DXd was initiated as the sixth-line therapy in combination with radiotherapy for brain metastases. After one treatment cycle, the patient achieved a partial response. T-DXd was discontinued in August 2022 due to recurrent anemia attributed to cardiac stenosis-related bleeding.

Conclusion::

The condition of the patient remained stable until May 2023, indicating a progression- free survival of over 24 months. This case suggests that T-DXd may offer long-term clinical benefits in patients with HER2-amplified advanced gastric cancer with brain metastases.

2024-12-10·JOURNAL OF CLINICAL ONCOLOGY

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer

Article

作者: Montorsi, Francesco ; Briganti, Alberto ; Mercinelli, Chiara ; Cigliola, Antonio ; Mattorre, Benedetta ; Necchi, Andrea ; Re, Chiara ; Ross, Jeffrey S. ; Raggi, Daniele ; Brembilla, Giorgio ; Colombo, Renzo ; Cogrossi, Laura L. ; Bellone, Matteo ; Pastorino, Giovanni L. ; Basile, Giuseppe ; Lucianò, Roberta ; Patanè, Damiano A. ; Tateo, Valentina ; Maiorano, Brigida A. ; Pavlick, Dean C. ; De Cobelli, Francesco ; Colecchia, Maurizio ; Moschini, Marco

PURPOSE:

To evaluate the activity and safety of nivolumab with nab-paclitaxel as neoadjuvant therapy, followed by radical cystectomy (RC) and postsurgical adjuvant nivolumab in patients with muscle-invasive bladder cancer (MIBC).

PATIENTS AND METHODS:

Eligible patients had an Eastern Cooperative Oncology Group performance status of ≤1 and a T2-4aN0-1M0 stage with >50% urothelial carcinoma histology and were ineligible for or refused cisplatin-based chemotherapy. Patients received four cycles of nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m 2 once on days 1 and 8, every 3 weeks, followed by RC, and then adjuvant nivolumab 360 mg once every 3 weeks × 13 cycles. The primary end point was the pathologic complete response (CR) rate (ypT0N0). Secondary end points were major pathologic response (ypT≤1N0), safety, event-free survival (EFS), and overall survival.

RESULTS:

Thirty-one patients were enrolled from December 2021 to June 2023; 19 (61.3%) had a cT2 stage, two (6.5%) had N1 stage, and 16 (51.6%) had a variant histology. Five patients (16.1%) received less than four full courses of neoadjuvant treatment because of treatment-related adverse events (TRAEs). Grade 3/4 TRAEs occurred in eight patients (25.8%). Twenty-eight patients underwent RC, and three refused RC after evidence of clinical CR and received a redo transurethral resection of the bladder tumor (reTURBT). The trial met its primary end point: 10 patients (32.3%; 95% CI, 16.7 to 51.4) achieved an ypT0N0 response. By including those who underwent reTURBT, 22 (70.9%; 95% CI, 55 to 87) achieved an ypT≤1N0-x response. After a median follow-up of 12 months (range, 5-22), two patients had a disease relapse after surgery. The 12-month EFS was 89.8% (95% CI, 79.5 to 100).

CONCLUSION:

To our knowledge, the first results from NURE-Combo trial suggest that this combination could expand the therapeutic opportunities of immune-chemotherapy in patients with MIBC.

1,038

项与白蛋白结合型紫杉醇相关的新闻（医药）

2024-12-12

·学术经纬

66%患者肿瘤几乎完全消失！《柳叶刀》子刊：刘真真团队探索乳腺癌治疗新方案

▎药明康德内容团队编辑新辅助治疗是乳腺癌综合治疗的重要组成部分，其目的是将不能手术的乳腺癌降期为可手术乳腺癌，不能保乳的乳腺癌降期为可保乳的乳腺癌等。早期人表皮生长因子受体2（HER2）阳性乳腺癌患者，在术前接受合理的新辅助治疗后能大幅提高病理完全缓解（pCR）率，提高保乳和保腋率，改善患者长期生存质量。既往研究显示，在化疗的基础上增加抗HER2治疗不仅能显著提高pCR率，还能改善患者的远期预后。目前，中国CSCO乳腺癌指南2023版和CBCS指南2022版对HER2阳性乳腺癌新辅助治疗方案一级推荐为TCbHP方案（多西他赛+卡铂联合曲妥珠单抗+帕妥珠单抗），但如何优化化疗药物，使HP双靶治疗患者可获得最佳的治疗效果以及相对可控的毒性，是乳腺癌领域的热点问题。近日，The Lancet Oncology发表河南省肿瘤医院刘真真教授团队的一项中国研究，结果表明，相比于标准的TCbH方案，白蛋白结合型紫杉醇联合曲妥珠单抗+帕妥珠单抗（nab-PHP）pCR率可从57.6%提升到66.3%，且患者耐受性更好。该研究通讯作者为河南省肿瘤医院刘真真教授，河南省肿瘤医院陈秀春、焦得闯、乔江华和王承为共同第一作者。截图来源：The Lancet Oncology HELEN-006是一项在中国6家医学中心开展的随机、3期临床试验。研究纳入年龄18~70岁的2~3期浸润性HER2阳性乳腺癌患者，所有患者均为女性，入组时均未接受过相关治疗，东部肿瘤协作组体能状态评分为0分或1分。研究人员以1：1的比例将患者纳入TCbHP方案组（337例）和nab-PHP方案组（332例）。研究主要终点为pCR率，即切除的乳腺标本和同侧腋窝淋巴结中均无残留浸润性癌的患者比例。中位随访时间为26个月。研究结果显示，62%（414/669）患者达到pCR，其中TCbHP方案组和nab-PHP方案组pCR率分别为66.3%（220/332）和57.6%（194/337）（OR=1.54，95%CI：1.10~2.14，P=0.011）。进一步分析可知，激素受体状态也影响了接受不同方案的pCR率，在激素受体阴性（雌激素和孕激素受体阴性）患者中，接受nab-PHP方案的患者pCR率显著高于接受TCbHP方案（86.0% vs. 70.1%，P=0.001），但研究人员并未在激素受体阳性患者中，观察到接受上述两种方案的患者pCR率之间存在显著差异。 ▲接受不同治疗方案的所有患者（A）、激素受体阴性（B）和激素受体阳性（C）患者分别接受nab-PHP方案（橙色）和TCbHP方案（蓝色）的pCR对比（图片来源：参考文献[1]）安全性方面，共有34%（228/669）患者发生至少一起3级或4级不良事件，其中nab-PHP方案组和TCbHP方案组分别为30%和38%。常见的3级或4级不良反应为恶心、腹泻和神经病变，两组均未报告药物相关死亡病例。总之，本次研究结果显示，相比于标准的TCbHP方案，nab-PHP方案在HER2阳性早期乳腺癌新辅助治疗更具潜在优势，特别是激素受体阴性的患者，pCR改善更为明显，该方案有望成为这部分患者的治疗新标准方案。点击文末“阅读原文/Read more”，即可访问The Lancet Oncology官网阅读完整论文。推荐阅读欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。参考资料 [1] Chen, Xiu-Chun et al.De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. The Lancet Oncology:Published November 26, 2024. DOI: 10.1016/S1470-2045(24)00581-3 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号留言联系。如有其他合作需求，请联系wuxi_media@wuxiapptec.com 分享，点赞，在看，传递医学新知

CSCO会议临床3期临床结果临床成功

2024-12-11

·氨基观察

“科八条”后，首家创新药企通过再融资审核；第十批国家集采明日上海开标

氨基观察-创新药组原创出品作者 | 黄凯 “科八条”后，首家创新药企通过再融资审核。 12月11日，迪哲医药公告，公司定向增发方案已经获上交所审核通过。这也是“科八条”发布以来，上交所首家未盈利企业再融资获得审核通过。集采又开始了。 12月11日，全国药品集采申报信息公开大会将在上海南郊宾馆进行，第十批全国药品集中采购即将在明日开标。此次国采纳入62种药品，覆盖心脑血管、消化、肿瘤、代谢等多个疾病领域，超过半数为依赖医院渠道销售的注射剂。葛兰素史克ADC国内新进展。 12月11日，据CDE官网，葛兰素史克注射用玛贝兰妥单抗拟优先审评，适应症为：与硼替佐米和地塞米松联合用于治疗既往接受过至少一种治疗的多发性骨髓瘤成年患者。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。 / 01 / 市场速递 1）第十批国家集采明日上海开标 12月11日，全国药品集采申报信息公开大会将在上海南郊宾馆进行，第十批全国药品集中采购即将在明日开标。此次国采纳入62种药品，覆盖心脑血管、消化、肿瘤、代谢等多个疾病领域，超过半数为依赖医院渠道销售的注射剂。 / 02 / 资本信息 1）迪哲医药增发方案获上交所审核通过 12月11日，迪哲医药公告，公司定向增发方案已经获上交所审核通过。这是“科八条”发布以来，上交所首家未盈利企业再融资获得审核通过。 / 03 / 医药动态 1）明慧医药注射用MHB036C获临床许可 12月11日，据CDE官网，明慧医药注射用MHB036C获临床许可，拟联合伏美替尼，用于治疗晚期肺癌患者。 2）嘉因生物EXG110注射液获临床许可 12月11日，据CDE官网，嘉因生物EXG110注射液获临床许可，拟定用于治疗成人法布雷病（α-半乳糖苷酶A缺乏症）患者。 3）葛兰素史克注射用玛贝兰妥单抗拟优先审评 12月11日，据CDE官网，葛兰素史克注射用玛贝兰妥单抗拟优先审评，适应症为：与硼替佐米和地塞米松联合用于治疗既往接受过至少一种治疗的多发性骨髓瘤成年患者。 4）永泰生物CAR-T疗法获突破性疗法认定 12月11日，永泰生物公告表示，CD19 CAR-T疗法获突破性疗法认定，适应症为：治疗25岁及以下复发/难治B细胞急性淋巴细胞白血病）患者。 / 04 / 海外药闻 1）BioNTech公布双抗组合疗法积极结果 12月10日，BioNTech在圣安东尼奥乳腺癌研讨会（SABCS）上，报告了在研双特异性抗体疗法BNT327（又名PM8002）与白蛋白紫杉醇联用，一线治疗局部晚期或转移性三阴性乳腺癌的1b/2a期临床试验结果。摘要数据显示，这一组合疗法的12个月、15个月和18个月总生存率分别为80.8%、78.1%和72.2%。 2）辉瑞蛋白降解疗法组合临床结果积极 12月10日，辉瑞宣布1b期临床试验TACTIVE-U子研究的初步数据显示，蛋白降解剂vepdegestrant与CDK4/6抑制剂abemaciclib联用，的3期临床试验推荐剂量患者临床获益率达到62.5%。 PS：欢迎扫描下方二维码，添加氨基君微信号交流。

优先审批细胞疗法免疫疗法突破性疗法ASH会议

2024-12-11

·医学新视点

超95%“最毒乳腺癌”患者疾病得到控制！创新组合疗法为患者添新选择

▎药明康德内容团队编辑日前，BioNTech公司在圣安东尼奥乳腺癌研讨会（SABCS）上报告了在研双特异性抗体疗法BNT327（又名PM8002）与白蛋白紫杉醇联用，一线治疗局部晚期或转移性三阴性乳腺癌的1b/2a期临床试验结果。摘要数据显示，这一组合疗法的12个月、15个月和18个月总生存率分别为80.8%、78.1%和72.2%。 BNT327是一款临床试验阶段的抗PD-L1/VEGF双特异性抗体，具有多重抗肿瘤机制，包括结合PD-L1并阻断PD-1/PD-L1相互作用，解除PD-1/PD-L1通路介导的免疫抑制作用，活化细胞毒性T淋巴细胞；中和VEGF，抑制血管内皮细胞增殖和新生血管的形成，抑制肿瘤生长；改善肿瘤微环境，提高细胞毒性T淋巴细胞在肿瘤微环境中的浸润，与免疫治疗起到协同作用。 BioNTech在今年11月宣布与普米斯生物技术公司（Biotheus）达成收购协议，获得BNT327的完整全球开发权益，以及普米斯候选药物管线及其双特异性抗体药物开发平台的全部权利。中期试验数据显示，截至2024年9月13日，中位随访时间为18.1个月，患者确认客观缓解率为73.8%，疾病控制率（DCR）为95.2%。中位缓解持续时间为13.5个月，中位总生存期尚未达到。值得一提的是，这款疗法在PD-L1表达水平很低（CPS<1）的患者中达到76.9%的确认客观缓解率，显示了它在治疗PD-1/PD-L1抑制剂单药难于治疗患者群体中的潜力。安全性方面，所有患者均出现治疗相关不良事件（TRAEs），59.5%为3或4级，未发生5级TRAEs。最常见（≥30%）的TRAE包括中性粒细胞减少症、白细胞减少症、贫血、蛋白尿、脱发、高甘油三酯血症、高胆固醇血症、鼻出血和乏力。目前，BNT327组合疗法正在中国进行的一项随机对照3期临床试验中接受评估，作为一线疗法治疗三阴性乳腺癌患者。治疗同一患者群体的全球性2期临床试验也在进行中。相关阅读 66%患者肿瘤几乎完全消失！《柳叶刀》子刊：河南肿瘤刘真真团队探索乳腺癌治疗新方案停药后仍可持续抗癌！联合疗法对抗“最常见”乳腺癌，复发风险降低25% 《柳叶刀-肿瘤学》：PFS几乎翻倍，疾病进展和死亡风险降低41%！创新口服疗法为乳腺癌患者带来新选择 3年无病生存、无复发率均超90%！直击“最毒乳腺癌”，复旦肿瘤方案登顶BMJ 参考资料： [1] BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer. Retrieved December 10, 2024, from https://www.fiercebiotech.com/biotech/biontechs-overall-survival-data-shows-promise-potential-keytruda-killer-breast-cancer [2] PS3-08: Interim Overall Survival of Patients with Locally Advanced or Metastatic Triple-Negative Breast Cancer treated with First Line PM8002/BNT327 in Combination with Nab-Paclitaxel in Phase Ib/II Study. Retrieved December 10, 2024, from https://sabcs.org/Portals/0/Documents/Formatted_Abstracts%2011-27%20Without%20Embargoed.pdf?ver=qjVzk5LPNjOteEIvNEYJFw%3d%3d 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，传递医学新知

临床2期免疫疗法临床3期临床结果并购

100 项与白蛋白结合型紫杉醇相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胰腺继发性恶性肿瘤	欧盟	WhiteOak Pharmaceutical BV	2024-07-24
胰腺继发性恶性肿瘤	冰岛	WhiteOak Pharmaceutical BV	2024-07-24
胰腺继发性恶性肿瘤	列支敦士登	WhiteOak Pharmaceutical BV	2024-07-24
胰腺继发性恶性肿瘤	挪威	WhiteOak Pharmaceutical BV	2024-07-24
转移性胰腺腺癌	美国	Teva Pharmaceuticals, Inc.	2023-05-11
胰腺腺癌	美国	Bristol Myers Squibb Co.	2013-09-06
非小细胞肺癌	日本	Taiho Pharmaceutical Co., Ltd.	2010-07-23
胰腺癌	日本	Taiho Pharmaceutical Co., Ltd.	2010-07-23
胃癌	日本	Taiho Pharmaceutical Co., Ltd.	2010-07-23
乳腺癌	中国	Abraxis BioScience, Inc.	2008-06-30
转移性乳腺癌	美国	Bristol Myers Squibb Co.	2005-01-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期乳腺癌	临床3期	中国	石药集团欧意药业有限公司	2023-04-27
PD-L1阳性三阴性乳腺癌	临床3期	阿根廷	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	智利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	捷克	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	法国	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	匈牙利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	意大利	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	墨西哥	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	秘鲁	Hoffmann-La Roche, Inc.	2019-12-17
PD-L1阳性三阴性乳腺癌	临床3期	波兰	Hoffmann-La Roche, Inc.	2019-12-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05659056 (SABCS2024) 人工标引	临床2期	HER2阳性乳腺癌新辅助 HER2 Positive	52	pyrotinib + trastuzumab + nab-paclitaxel	觸窪願選醖衊獵積積簾(積鹽構築鏇衊鬱願鹽憲) = 積鏇繭鹹積壓築廠淵艱鏇網淵獵願構獵窪選夢 (獵鏇積壓積廠鏇網遞齋, 29.0 ~ 56.7) 更多	积极	2024-12-10
				pyrotinib + trastuzumab + nab-paclitaxel (HER2-enriched subtype)	觸窪願選醖衊獵積積簾(積鹽構築鏇衊鬱願鹽憲) = 鑰鏇糧繭積範觸積鹹獵鏇網淵獵願構獵窪選夢 (獵鏇積壓積廠鏇網遞齋, 37.9 ~ 73.2)
NCT02754726 (CTgov)	临床2期	转移性胰腺导管腺癌	35	nivolumab+albumin-bound paclitaxel+Gemcitabine+Paricalcitol+cisplatin	積醖鏇憲鑰選觸鏇齋鹹(獵鑰鬱製選夢顧積壓壓) = 鹹繭夢繭鹽網夢艱壓願齋遞鏇範製衊鬱製襯膚 (齋淵獵餘襯顧鹹窪獵夢, 膚繭顧鑰糧夢艱壓網蓋 ~ 蓋襯廠夢糧網夢艱網艱) 更多	-	2024-12-10
NCT03768414 (SWOG 1815, CTgov)	临床3期	不可切除的肝内胆管癌 \| 晚期胆道癌 \| 胆囊肿瘤 ... 更多	452	Nab-paclitaxel+Gem+Cisplatin (Gem+Cisplatin+Nab-paclitaxel)	鬱壓獵範壓繭衊願夢淵(鑰顧襯願衊齋鹽構鏇鬱) = 鏇憲鏇醖鏇醖製選鹽觸鹽遞鏇鹹膚鏇鏇構鹽膚 (範衊齋襯壓鏇糧窪繭鏇, 繭製選膚蓋廠簾鏇糧獵 ~ 範鹹廠糧範醖積範鏇觸) 更多	-	2024-10-22
				Gemcitabine+Cisplatin (Gemcitabine + Cisplatin)	鬱壓獵範壓繭衊願夢淵(鑰顧襯願衊齋鹽構鏇鬱) = 膚蓋顧網構餘窪糧顧鏇鹽遞鏇鹹膚鏇鏇構鹽膚 (範衊齋襯壓鏇糧窪繭鏇, 選遞範製壓觸繭窪鬱製 ~ 簾鹹鑰憲製襯鹽網網鬱) 更多
ASTRO	N/A	局部晚期食管鳞状细胞癌新辅助	136	Weekly cisplatin/nab-paclitaxel	築衊簾夢觸淵選鹹廠餘(鬱顧繭構願顧願鹹壓構) = 淵衊艱簾鹹夢夢醖壓襯鏇鑰積選範廠鏇膚廠構 (糧蓋壓衊餘夢窪積蓋簾 ) 更多	积极	2024-10-01
				Tri-weekly cisplatin/nab-paclitaxel	築衊簾夢觸淵選鹹廠餘(鬱顧繭構願顧願鹹壓構) = 鑰築醖壓構醖範觸願獵鏇鑰積選範廠鏇膚廠構 (糧蓋壓衊餘夢窪積蓋簾 ) 更多
NCT05821556 (VESPA, Pubmed \| BMC Cancer)	临床2期	转移性胰腺腺癌 CA 19.9	240	VPA/SIM plus gemcitabine/nab-paclitaxel-based regimens	顧夢蓋鑰選襯製構膚壓(糧鹽廠獵鹹構繭夢襯鹹) = 網遞壓選積繭醖鹹廠窪膚積廠範窪夢積鏇遞壓 (鹹觸簾鹽獵願憲簾鑰鹽 )	-	2024-09-19
				Chemotherapy alone	顧夢蓋鑰選襯製構膚壓(糧鹽廠獵鹹構繭夢襯鹹) = 艱範鏇顧廠選膚積網積膚積廠範窪夢積鏇遞壓 (鹹觸簾鹽獵願憲簾鑰鹽 )
NCT04917900 (not available, ESMO2024) 人工标引	临床2期	HER2阳性乳腺癌新辅助 HER2 Positive	214	Pyrotinib plus albumin-bound paclitaxel and trastuzumab (HLX02)	觸選鑰壓膚顧餘積鹽糧(憲襯願衊廠製鏇憲簾繭) = 膚憲鑰艱鹹網膚艱網築鬱願鑰蓋鹽獵積淵觸願 (衊憲繭鏇構襯廠鹹築積, 55.65 ~ 69.86) 更多	积极	2024-09-16
NCT05244993 (ESMO2024) 人工标引	临床2期	晚期三阴性乳腺癌一线	33	AK105, anlotinib, nab-P	願構觸糧齋淵壓壓鏇觸(糧齋積顧鑰憲餘構齋淵) = 製廠築獵餘選製積遞窪襯遞願網憲範夢衊構糧 (壓淵廠廠淵窪淵夢選齋, 60.65 ~ 93.45) 更多	积极	2024-09-16
NCT05026905 (TCOG T5221, ESMO2024) 人工标引	临床2期	胰腺癌一线	50	GASL (Gemcitabine plus nab-paclitaxel and S-1/leucovorin	(製糧積鑰夢夢鏇壓構鑰) = 積網淵顧糧鹽鏇齋蓋築簾窪鬱鏇膚壓鑰壓鏇醖 (顧製衊糧顧蓋壓壓築餘 ) 更多	积极	2024-09-16
				GAP (Gemcitabine plus nab-paclitaxel and oxaliplatin)	(製糧積鑰夢夢鏇壓構鑰) = 糧構蓋鹹蓋簾鏇壓選積簾窪鬱鏇膚壓鑰壓鏇醖 (顧製衊糧顧蓋壓壓築餘 ) 更多
NCT04257448 (SEPION/AIO-PAK-0118, ESMO2024)	临床1/2期	晚期胰腺导管腺癌巩固	73	Nab-paclitaxel/gemcitabine with epigenetic targeting	構襯簾繭夢獵齋構鏇窪(鹹鏇鹽願鬱鏇艱獵壓觸) = 簾蓋衊鏇鏇壓鏇糧廠製繭鏇壓膚艱醖鏇願構構 (鑰觸繭鏇膚醖鹽餘簾鏇, 8.1 ~ 14.9) 更多	积极	2024-09-16
				Nab-paclitaxel/gemcitabine without epigenetic targeting	構襯簾繭夢獵齋構鏇窪(鹹鏇鹽願鬱鏇艱獵壓觸) = 夢夢鬱繭憲簾醖鑰夢襯繭鏇壓膚艱醖鏇願構構 (鑰觸繭鏇膚醖鹽餘簾鏇, 8.2 ~ 23.3) 更多
ESMO2024	N/A	头颈部鳞状细胞癌	-	Pembrolizumab, nab-paclitaxel, and platinum	鏇製蓋觸夢膚顧醖選衊(遞艱獵鬱艱夢蓋餘鹹膚) = Upregulation of serum IFN-γ and IL8 was significantly associated with the occurrence of most TRAEs, such as fatigue, hyper/hypothyroidism, and rash 醖夢鹽鑰鹽廠製齋憲膚 (衊衊蓋選襯糧糧蓋膚鏇 )	-	2024-09-14